← Back to patent-cliff list
Fexlamose
Tier C — Watch / tradeFexlamose
Trinity College Dublin
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ACE2
Indications (approved)：Chronic obstructive pulmonary disease, Lung disease, Cystic fibrosis
Regional status
US
-
2020-10-26
EU
-
2020-10-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fexlamose?
Approved indications include: Chronic obstructive pulmonary disease, Lung disease, Cystic fibrosis.
When does the Fexlamose patent expire?
No public expiry year is available for Fexlamose yet; this page updates once verified.
How do I get a quote for Fexlamose intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01